Complete response rate in Nektar melanoma trial hits 34%

Complete response rate in Nektar melanoma trial hits 34%

Source: 
Fierce Biotech
snippet: 

Nektar Therapeutics has posted updated data on its NKTR-214-Opdivo cocktail in first-line melanoma. The data feature four more complete responses, bringing the rate up 10 percentage points to 34%.